PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-04-08
Target enrollment:
Participant gender:
Summary
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and
pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.